Athira Pharma Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
70
- Stock Symbol
-
ATHA
- Share Price
-
$1.77
- (As of Wednesday Closing)
Athira Pharma General Information
Description
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Contact Information
- 18706 North Creek Parkway
- Suite 104
- Bothell, WA 98011
- United States
Athira Pharma Timeline
Athira Pharma Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.77 | $1.76 | $1.33 - $4.41 | $66.8M | 38.1M | 178K | -$3.17 |
Athira Pharma Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | (107,466) | (99,055) | 252,897 | 887,318 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (119,559) | (94,794) | (54,374) | (19,710) |
| Net Income | (120,522) | (95,639) | (54,853) | (19,955) |
| Total Assets | 184,700 | 258,153 | 332,008 | 279,563 |
| Total Debt | 1,672 | 1,911 | 1,920 | 1,000 |
Athira Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Athira Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Athira Pharma Comparisons
Industry
Financing
Details
000000
000000
Athira Pharma Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cassava Sciences | Formerly VC-backed | Austin, TX | 00 | 00000 | 000000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | New York, NY | 00 | 000.00 | 00000000 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 000000&0 | |
| 0000000 | Venture Capital-Backed | Framingham, MA | 00 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Weston, FL | 0 | 000.00 | 00000000 | 000.00 |
Athira Pharma Patents
Athira Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230062006-A1 | Methods of treating parkinson's disease and/or lewy body disease or disorder(s) | Pending | 23-Jul-2021 | 000000000 | 0 |
| US-20230070758-A1 | Methods of treating alzheimer's disease | Pending | 16-Jul-2021 | 0000000000 | |
| JP-2023550543-A | Bicyclic compounds and their use for the treatment of diseases | Pending | 02-Nov-2020 | ||
| AU-2021371026-A1 | Bicyclic compounds and uses thereof for the treatment of diseases | Pending | 02-Nov-2020 | 0000000000 | |
| CA-3196582-A1 | Bicyclic compounds and uses thereof for the treatment of diseases | Pending | 02-Nov-2020 | C07D487/04 |
Athira Pharma Executive Team (17)
Athira Pharma Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barbara Kosacz JD | Self | Board Member | 000 0000 |
| Grant Pickering | Self | Board Member | 000 0000 |
| James Johnson | Self | Board Member | 000 0000 |
| John Fluke Jr. | Self | Board Member | 000 0000 |
| Joseph Edelman | Perceptive Advisors | Board Member | 000 0000 |
Athira Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Athira Pharma ESG
Risk Overview
Risk Rating
Updated October, 01, 2023
25.56 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Biotechnology
Subindustry
00 of 399
Rank
Percentile
